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Abstract
Background: There has been major improvement in the survival of HIV-1 infected individuals since the South
African Government introduced highly active anti-retroviral therapy (HAART) in the public sector in 2004. This has
brought new challenges which include the effects of stavudine-related toxicities.
Methods: Prospective analysis of a cohort of 9040 HIV-infected adults who were initiated on HAART at the
Themba Lethu Clinic (TLC) in Johannesburg between April 1, 2004 to December 31, 2007, and followed up until
June 30, 2008.
Results: Amongst the 9040 study subjects, 8497(94%) were on stavudine based therapy and 5962 (66%) were
women. The median baseline CD4 count was 81 cells/mm
3 (IQR 29-149). Median follow up on HAART was 19
months (IQR: 9.1-31.6). The proportion of HAART-related side effects for stavudine compared to non-stavudine
containing regimens were, respectively: peripheral neuropathy,17.1% vs. 11.2% (p < 0.001); symptomatic
hyperlactataemia, 5.7% vs. 2.2% (p < 0.0005); lactic acidosis, 2.5 vs. 1.3% (p = 0.072); lipoatrophy, 7.3% vs. 4.6% (p <
0.05). Among those on stavudine-based regimens, incidence rates for peripheral neuropathy were 12.1 cases/100
person-years (95%CI 7.0-19.5), symptomatic hyperlactataemia 3.6 cases/100 person-years (95%CI 1.2-7.5), lactic
acidosis 1.6 cases/100 person-years (95%CI 0.4-5.2) and lipoatrophy 4.6 cases/100 person-years (95%CI 2.1-9.6).
Females experienced more toxicity when compared to males in terms of symptomatic hyperlactataemia (p <
0.0001), lactic acidosis (p < 0.0001), lipoatrophy (p < 0.0001) and hypertension (p < 0.05).
Conclusions: We demonstrate significant morbidity associated with stavudine. These data support the latest WHO
guidelines, and provide additional evidence for other resource limited HAART rollout programs considering the
implementation of non-stavudine based regimens as first line therapy.
Background
By the end of 2008, an estimated 33.4 million people
worldwide were living with human immunodeficiency
virus (HIV) infection [1]. Southern Africa continues to
bear a disproportionate share of the global burden of
HIV with 67% of the HIV infections worldwide, of which
68% of them were amongst adults. This region also
accounted for 72% of the world’s AIDS related deaths [1].
South Africa’s 2009 HIV prevalence rate in the adult
population (aged 15-49 years) was estimated to be 17.8%
[2].
There has been an increase in the provision of highly
active antiretroviral therapy (HAART), with up to 44% of
adults and children estimated to be receiving therapy with
a profound reduction in mortality [2] and, with adherence
to HAART it is possible to transform HIV from a fatal
infection to a chronic and manageable illness [3-5].
However, some of the anti-retroviral agents used in
HAART regimens have severe side effects. Prominent
amongst these drugs is stavudine, the use of which is asso-
ciated with lactic acidosis/symptomatic hyperlactataemia,
lipoatrophy, and peripheral neuropathy [6]. Other side
effects of stavudine use include dyslipidaemia and insulin
resistance, and it is an independent risk factor for the
development of new onset diabetes mellitus [7]. Despite
these serious side effects up to 60% of HIV-positive
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stavudine [8,9].
T h ea i mo ft h i ss t u d yw a st om a k eu s eo fal a r g e( N=
9040) clinic-based survey of HIV-positive patients newly
initiated onto HAART over a period of three years, to
compare and describe the effect of stavudine based ther-
apy on acute and chronic toxicities after initiation of
HAART. We present baseline data gathered before the
initiation of HAART and data collected for three years
with each patient having a minimum of six months of
follow-up. This is the largest study of the side effects of
stavudine therapy conducted to date in a South African
HIV-positive population.
Methods
Study population
The study population included HIV-1 infected indivi-
duals attending the Themba Lethu Clinic, a public sector
HAART rollout facility based at the Helen Joseph Hospi-
tal, a teaching hospital attached to the University of the
Witwatersrand, Johannesburg, South Africa. This clinic
provides free antiretroviral therapy and other specialized
services, and is one of the largest HAART rollout clinics
in Africa. The program is funded by the South African
National and Gauteng Departments of Health, with sup-
port from Right to Care funded by USAID and PEPFAR.
Treatment
HAART was initiated in accordance with the 2004 South
African National Antiretroviral Treatment Guidelines,
which include initiation criteria of a CD4 count ≤ 200
cells/mm
3 or WHO stage 4 AIDS defining illness irrespec-
tive of CD4 count [10]. The first line therapy consisted of
stavudine, lamuvidine and efavirenz or nevirapine; how-
ever kaletra (ritonavir/lopinavir) was used as part of the
first line therapy regimen if there were contra-indications
to other first line drugs [10]. Until October 2007, stavu-
dine was dosed according to patients’ body weight: 30 mg
for those < 60 kg and 40 mg for those ≥ 60 kg. From
October 2007, a universal 30 mg dose was introduced and
40 mg tablets of stavudine were withdrawn from the clinic.
Single drug substitutions were permitted depending on the
underlying clinical presentation of the patient.
Clinical and laboratory measurements
Patients who met the criteria for initiating of HAART
received adherence counseling and screening for oppor-
tunistic infections prior to initiation of therapy. A history
and physical examination was performed at every visit.
All patients had a baseline chest X-ray. Laboratory moni-
toring was performed according to the clinic protocol.
Other serum biochemical tests were carried out as clini-
cally indicated. The results of these tests were not avail-
able for analysis as the majority of patients were seen and
diagnosed at other clinics where they would present for
acute medical problems, and where their HAART regi-
men was modified. However, their diagnoses and new
HAART regimens were captured for this study.
Diagnosis and definitions
Body mass index (BMI) was defined as body weight
divided by the height, squared (kg/m
2). Patients who pre-
sented with symptoms of numbness or dysesthesia after
initiation of HAART were defined as having peripheral
neuropathy due to HAART, once other causes were
excluded. Symptomatic hyperlactataemia was defined as
t h ep r e s e n c eo fs u g g e s t i v es y m p t o m sw i t ha nu n c u f f e d
venous lactate level > 5 mmol/L with no evidence of a
metabolic acidosis; and lactic acidosis was defined as an
uncuffed lactate > 5 mmol/l and arterial pH < 7.35 or a
total venous CO2 < 20 mmol/l, with other causes such as
sepsis, renal failure, diabetic ketoacidosis and dehydration
excluded. Pancreatitis was defined as the presence of
abdominal symptoms with a serum amylase > 125 U/L
and lipase > 60 U/L. The definition of lipoatrophy was
based on the development of peripheral fat wasting (face,
arms, buttocks or thighs) and/or central abdominal fat
accumulation, and may include enlarged breasts. This was
usually reported by the patient and confirmed by the doc-
tor or, initially diagnosed by the doctor with patient con-
firmation. Hypertension was defined by the presence of
three separate readings of systolic blood pressure > 140
mmHg and a diastolic blood pressure > 90 mmHg. Dia-
betes was defined as the presence of symptoms with a fast-
ing glucose of > = 7 mmol/L or a random blood glucose of
11.1 mmol/L. Dyslipidaemias were defined by the presence
of abnormal lipid levels which included an elevated total
cholesterol of > 5 mmol/L, an elevated triglyceride level of
> 1.7 mmol/L, and elevated LDL level of > 3 mmol/L.
Data collection and statistical analysis
We analyzed prospectively collected longitudinal cohort
data from patients attending the clinic. Clinical data from
patient records were captured onto an electronic database
via a medical management software system, Therapy
Edge-HIV™ (Associated Biological Systems, South Africa).
Data was analyzed using the SAS
® 9.1 statistical software
package (SAS Institute, Inc., North Carolina, USA). Base-
line characteristics of the study sample were summarized
using simple proportions and medians with interquartile
ranges. Differences in proportions of the toxicities were
compared by initiating regimen with Chi-squared tests.
Study subjects were followed from HAART initiation to
the earliest of 1) death; 2) loss to follow up; 3) develop-
ment of toxicity or 4) censor date 31 December 2008. Inci-
dence rates with 95% confidence intervals for toxicity were
calculated and compared by initiating regimen type (stavu-
dine-based versus other). Crude and adjusted estimates of
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toxicity were estimated using Cox proportional hazard
models. Models were controlled for confounding by base-
line body mass index, CD4 count, age, and gender.
Though the majority of subjects initiated HAART prior to
the introduction of the universal 30 mg stavudine dose,
models were also adjusted for time period in which
HAART was initiated (prior to or post October 2007).
Kaplan Meier curves were used to estimate crude time to
diagnosis of therapy-related complications stratified by
initiated regimen. Subjects with existing toxicity at initia-
tion of HAART were excluded from these analyses.
Use of the data for the study was approved by the
Human Research Ethics Committee (Medical) of the
University of the Witwatersrand.
Results
Between 1 April 2004 and 1 July 2008, a total of 15,928
HIV-infected adults enrolled in care at the Themba Lethu
Clinic. Of these, 5104 (32%) had early stage HIV infection
and did not qualify for HAART, whilst the remaining
10,824 (68%) subjects were initiated on HAART. The
study sample included the 9040 patients initiated on treat-
ment between 1 April 2004 and 31 December 2007. The
cohort profile is summarized in Figure 1.
Baseline characteristics of the study population
The baseline characteristics of the study cohort are sum-
marized in Table 1. Two thirds of the study group was
female. The majority of patients were in the age group
25-44 years. Even though 46.9% of the total study popula-
tion were defined as being at only WHO Stage 1 for AIDS,
they were already on HAART, indicating that their CD4
count rates were below 200 cells/mm
3 and this was con-
firmed by the median baseline CD4 count of 81 cells/mm
3
(IQR: 29-149).
Ninety four percent of patients were on stavudine
based regimens at baseline, with 79% of these initiated
on stavudine, lamivudine and efavirenz as per the 2004
South African National guidelines [10], while a smaller
number were initiated on zidovudine- (3.4%) and teno-
fovir-based regimens (0.7%).
Retention in care
The median time to follow up for this cohort on HAART
was 19 months (IQR: 9.1-31.6). At the end of the study
period, a total of 6415 patients (71%) were still alive and
in care, 469 were confirmed deceased and a further 2156
were considered lost to follow up. Patients were consid-
ered lost to follow up if they missed their last scheduled
appointment by more than 90 days or at least 180 days
had lapsed since their last visit. It can be assumed that
some of the patients who are lost to follow up may have
died and so in total, there were 2,625 (16.5%) patients in
this cohort who were either lost to follow up or dead by
the end of the study period (see Figure 1).
Response to HAART
The patients had a median baseline CD4 count of 81 cells/
mm
3 (IQR 29-149). There was a significant (p < 0.0001)
increase in the CD4 count after initiation with a median of
205 cells/mm
3 (IQR 132-293) by 6 months on treatment.
After six months of therapy, there was no significant
change in BMI (means ± SD; 22.4 ± 5.0 and 23.7 ± 5.5
respectively).
Acute and chronic toxicities
Amongst the 9040 patients on therapy, 2488 patients
(27.5%) had one or more incident toxicities recorded after
treatment initiation. In terms of acute HAART-related
toxicities, the proportion of patients diagnosed with per-
ipheral neuropathy was significantly higher in the group
receiving stavudine-based therapy (17.1% vs. 11.2%; p <
0.001) compared to those on non-stavudine based therapy
(Table 2). Peripheral neuropathy was reported equally in
both genders (approximately 17%), with no difference in
time to development between the drug groups. There was
also a significantly higher proportion of patients on stavu-
dine based therapy presenting with symptomatic hyperlac-
tataemia when compared to those on non-stavudine based
therapy (5.75 vs. 2.2%, p < 0.0005) (Table 2), with females
more frequently affected than males (7.1% vs. 2.5%; p <
0.0001). Although the rate of development of lactic acido-
sis was the same for both drug groups, it was experienced
more frequently in females than males (3.3% vs. 0.8%; p <
0.0001). The median time to onset was the same for both
drug groups. Pancreatitis was equally rare in both treat-
ment groups (see Table 2); both genders were equally
affected, with the time to onset being the same in both
drug groups. When compared to those on non-stavudine
based regimens, those receiving stavudine had higher inci-
dence rates of several toxicities including peripheral neu-
ropathy [12.1/100 person-years (95%CI 7.0-19.5) vs. 7.9/
100 person-years (95%CI 6.0-10.1)], symptomatic hyper-
lactataemia [3.6/100 person-years (95%CI 1.2-7.5) vs.1.4/
100 person-years (95%CI 0.7-2.5)], and lactic acidosis [1.6/
100 person-years (95%CI 0.4-5.2) vs. 0.8/100 person-years
(95%CI 0.3-1.7)] (Table 3).
In terms of the chronic HAART-related metabolic com-
plications, 7.3% presented with lipoatrophy on stavudine
based therapy, compared to 4.6% (p < 0.05) patients on
non-stavudine based therapy. The median time to devel-
opment of lipoatrophy was similar across the 2 treatment
groups. Lipoatrophy was more predominantly seen in
female than male patients (10.0% vs. 1.6%; p < 0.0001).
Incidence rates for lipoatrophy were slightly higher in the
stavudine based therapy group [3.0/100 person-years (95%
CI 1.9-4.4) versus 4.6/100 person-years (95%CI 2.1-9.6)]
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percent of patients presented with hypertension, while
only 0.3% presented with diabetes and 1.3% with dyslipi-
daemia on stavudine based therapy. Similar proportions
developing these conditions were observed in both groups
(Table 2). However, hypertension developed more quickly
(p < 0.05) in patients taking stavudine than in those not
receiving this drug (Table 2). Hypertension was less com-
mon in females than males (1.8% vs. 2.4%; p < 0.05) but
females and males were equally affected in terms of dia-
betes and dyslipidaemia.
In multivariate analyses adjusted for age, gender, base-
line BMI, CD4 counts and the time period initiating
HAART, the use of stavudine continued to be associated
15928 HIV-infected patients 
5104 patients had early 
stage HIV infection and 
did not require therapy 
638 patients were 
treatment experienced 
or on second line 
therapy 
10186 HIV-infected patients on 
HAART 
1146 patients initiated 
HAART outside the 
study period 
9040 HIV-infected patients 
initiated HAART at TLC during the 
study period 
2156 Lost to follow up  469 Died  6415 Survived 
Figure 1 Profile of the Study Cohort.
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peripheral neuropathy (HR 2.02; 95% CI 1.35-3.03),
symptomatic hyperlactataemia (HR 2.81; 95% CI 1.26-
6.31), lactic acidosis (adjusted HR 2.55; 95% CI 0.81-
8.00) and diabetes mellitus (adjusted HR 2.07; 95% CI
0.28-15.21) though some of these estimates lacked preci-
sion (Table 3).
Figures 2, 3, 4 and 5 present Kaplan Meier curves for
the crude estimates of the time to development of
HAART-related toxicities by initiating regimen. Those
initiated on stavudine based regimens were more likely to
develop peripheral neuropathy (log rank p < 0.001),
hyperlactataemia (log rank p < 0.001), lactic acidosis (log
rank p = 0.098) or lipoatrophy (log rank p < 0.05) than
those on non-stavudine based regimens.
Other risk factors for development of toxicity
Age, CD4 counts and WHO staging at baseline did not
appear to increase the risk of any adverse events after
HAART initiation; however, BMIs at baseline did signifi-
cantly increase the risk of both symptomatic hyperlacta-
taemia and lactic acidosis. Relative to a baseline BMI of <
25 kg/m
2, an increased risk of symptomatic hyperlactatae-
mia was seen for those with a BMI of 25-30 kg/m
2 (RR
1.7; 95% CI 1.34-2.14, p < 0.0001) and those with a BMI of
>3 0k g / m
2 (RR 1.82; 95% CI 1.35-2.44, p < 0.0001). The
same was seen with lactic acidosis, where an increased risk
was seen for those with a BMI of 25-30 kg/m
2 (RR 2.52;
95% CI 1.74-3.65, p < 0.0001) and those with a BMI of >
30 kg/m
2 (RR 3.10; 95% CI 2.00-4.79, p < 0.0001) when
compared to subjects with a BMI of < 25 kg/m
2.
Discussion
This study describes data of three years of follow up of
9040 HIV-infected adults initiated on anti-retroviral treat-
ment at the Themba Lethu Clinic, Johannesburg, South
Africa. This high number of patients demonstrates the
ability of rolling out a successful HAART programme
despite being in a resource limited environment, and this,
at a rapidity and scale that compares with reports from
other African countries [6,11,12].
Despite the fact that stavudine is associated with signifi-
cant complications, a large proportion of low and middle-
income countries still use stavudine based HAART as first
line therapy [8,9], mainly because of the cost implications
of alternative drugs. In the present study nearly 30% of
patients had to switch to non-stavudine based regimens,
due to major side effects. These findings concur with
those from another large study in South Africa where 21%
of patients switched regimens over a similar time period
[6].
This study provides estimates of the pattern of toxicities,
the predominant ones being peripheral neuropathy, symp-
tomatic hyperlactataemia, and lipoatrophy. Our incidence
Table 1 Cohort characteristics at baseline
Characteristic Baseline value
Gender
Female
Male
(N = 9040)
5962 (66)
3078 (34)
Age (years)
< 25 years
25-34 years
35-44 years
45-54 years
> 55 years
(N = 9040)
551 (6.1)
3822 (42.3)
3216 (35.5)
1173 (13.0)
277 (3.1)
WHO AIDS classification
Stage 1
Stage 2
Stage 3
Stage 4
(N = 8714)
4086 (46.9)
1310 (15)
2507 (28.8)
811 (9.3)
HAART
d4T/3TC/EFV
d4T/3TC/NVP
d4T/3TC/Kaletra
AZT containing regimen
TDF containing regimen
other
(N = 9040)
7138 (79)
690 (7.6)
669 (7.4)
308 (3.4)
59 (0.7)
176 (1.9)
BMI (kg/m
2) 22.4 ± 5.0 (N = 7010)
CD4 count (cells/mm
3) 81 (29-149) (N = 7605)
Follow up time on HAART (months) 19.0 (9.1-31.6) (N = 9040)
Data is expressed as N (%) except for BMI (mean ± SD), CD4 count (median,
IQR) and follow up time on HAART (median, IQR). WHO, World Health
Organization, d4T, stavudine; 3TC, lamivudine; EFV, efavirenz; NVP, nevirapine;
kaletra, ritonavir/lopinavir; AZT, zidovudine; TDF, tenofovir.
Table 2 Frequency of and time to HAART associated toxic
complications by initiating regimen
Condition Stavudine
(N = 8497)
Other drugs
(N = 543)
Peripheral neuropathy
Frequency
Time to diagnosis
1454 (17.1)*
6.7 (3.8-111.8)
61 (11.2)*
5.1 (3.1-11.7)
Symptomatic
hyperlactataemia
Frequency
Time to diagnosis
487 (5.7)*
14.5 (10.6-20.9)
12 (2.2)*
11.6 (8.7-19.4)
Lactic Acidosis
Frequency
Time to diagnosis
214 (2.5)
10.8 (9.0-13.5)
7 (1.3)
11.2 (9.0-13.5)
Pancreatitis
Frequency
Time to diagnosis
14 (0.2)
10.4(4.0-13.0)
1 (0.2)
8.3 (8.3-8.3)
Lipoatrophy
Frequency
Time to diagnosis
616 (7.3)**
17.0 (11.4-23.1)
25 (4.6) **
15.0 (10.5-24.8)
Hypertension
Frequency
Time to diagnosis
167 (2.0)
9.7 (4.6-18.4)**
17 (3.1)
16.3 (9.3-30.5)**
Diabetes
Frequency
Time to diagnosis
28 (0.3)
22.4 (12.5-28.1)
1 (0.2)
9.0 (9.0-9.0)
Dyslipidaemia
Frequency
Time to diagnosis
109 (1.3)
24.6 (17.4-34.0)
9 (1.7)
19.1 (15.3-26.1)
Data is given as n (%) for prevalence and median (IQR) for time to diagnosis;
*p < 0.005, **p < 0.05 versus group receiving stavudine.
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were much higher compared to other African studies: 5.2/
100 person-years in Rwanda [13] and 2.8/100 person-years
in another site in South Africa [6]. The variability in these
rates could be because there are no grading protocols for
the severity of peripheral neuropathies. Our incidence
rates of lactic acidosis were similar to a study from another
province in South Africa, 1.6 versus 1.9/100 person-years
[14]. The proportion of lactic acidosis was slightly higher
compared to another study from Botswana [15], 2.5% ver-
sus 1% in our cohort. When compared to this same study
[15], the proportion developing symptomatic hyperlacta-
taemia were much higher in our sample (5.7% versus 2%).
The median time to the development of lactic acidosis was
a little later in our study when compared to another study
from South Africa (10.8 months versus 7.5 months) [14].
In terms of the chronic toxicities, incidence rates of
lipoatrophy were 4.6/100 person-years on stavudine
based therapy and 3.0/100 person-years on the non-sta-
vudine based therapy. One study from Rwanda [13],
where patients were also on stavudine based regimens
showed a similar incidence rate of lipoatrophy to that
reported in the present study at 4.7/100 person-years,
while one other study from South Africa [6] showed a
lower incidence rate of 1.4/100 person-years. Another
study from Rwanda showed a much higher proportion
(34%) of patients developing lipoatrophy [16]. The rea-
son for this wide variation in lipoatrophy rates specifi-
cally, is possibly due to different diagnostic criteria used
for identifying cases. Thus, in the present study and in
the studies showing low but similar rates [6,13], only
cases that were severe enough to warrant a regimen
change were noted. In the study showing a much higher
proportion, milder cases of lipodystrophy that did not
require a regimen change, were also recorded [16]. An
objective case definition of lipodystrophy has been
developed [17]; however, it requires access to DEXA
and CT imaging technology, which is often not available
in resource-limited settings. Therefore, an alternative
consensus definition for the diagnosis of lipodystrophy
is required for such environments.
A very small number of patients presented with dia-
betes (0.3%) and dyslipidaemias (1.3%). However, this
could be because lipid or glucose levels were only tested
when clinically suspected due to cost implications,
therefore probably underestimating the true prevalence
of dyslipidaemia and diabetes.
T h em a j o rs t r e n g t ho ft h i ss t u d yi st h el a r g es a m p l e
s i z e .T h i sc o h o r ti ss i m i l a rt om a n yo t h e rr e s o u r c e -
limited settings where there is rapid scaling-up of
Table 3 Crude and adjusted effects of stavudine use on toxicity initiated on HAART
Toxicity No events Person
Time (years)
Rate/100 pys*
(95% CI)
‡
Crude HR
§
(95% CI)
‡
Adjusted† HR
(95% CI)
‡
Peripheral Neuropathy
Other
d4T-based
61
1454
775.9
12055.5
7.9 (6.0-10.1)
12.1 (7.0-19.5)
1.0
1.53 (1.19-1.98)
1.0
2.02 (1.35-3.03)
Symptomatic hyperlactataemia
Other
d4T-based
12
487
852.3
13690.9
1.4 (0.7-2.5)
3.6 (1.2-7.5)
1.0
2.70 (1.52-4.79)
1.0
2.81 (1.26-6.31)
Lactic acidosis
Other
d4T-based
7
214
848.3
13805.9
0.8 (0.3-1.7)
1.6 (0.4-5.2)
1.0
2.09 (0.99-4.44)
1.0
2.55 (0.81-8.00)
Pancreatitis
Other
d4T-based
1
14
858.9
14126.2
0.1 (0.003-0.6)
0.1 (0.02-2.6)
1.0
0.95 (0.13-7.21)
1.0
0.40 (0.05-3.16)
Lipoatrophy
Other
d4T-based
25
616
834.0
13534.3
3.0 (1.9-4.4)
4.6 (2.1-9.6)
1.0
1.67 (1.12-2.50)
1.0
1.60 (0.92-2.77)
Hypertension
Other
d4T-based
17
167
845.0
13929.0
2.0 (1.2-3.2)
1.2 (0.2-4.0)
1.0
0.66 (0.40-1.08)
1.0
0.83 (0.39-1.78)
Diabetes Mellitus
Other
d4T-based
1
28
859.0
14122.7
0.1 (0.003-0.6)
0.2 (0.02-2.6)
1.0
1.90 (0.26-14.04)
1.0
2.07 (0.28-15.21)
Dyslipidaemia
Other
d4T-based
9
109
856.5
14097.2
1.1 (0.4-2.0)
0.8 (0.2-4.0)
1.0
0.82 (0.41-1.61)
1.0
0.61 (0.27-1.40)
*pys = person years.
§ HR = hazard ratio estimated from Cox proportional hazard models.
‡ 95% CI = 95% confidence interval.
† All models adjusted for age, gender, baseline CD4 count, baseline body mass index and time at which HAART was initiated (either prior to or post October 2007).
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Page 6 of 10Figure 2 Kaplan Meier crude estimates of time to development of peripheral neuropathy by initiating regimen (subjects with
peripheral neuropathy at initiation of HAART were not included in the analysis).
Figure 3 Kaplan Meier crude estimates of time to development of hyperlactataemia by initiating regimen.
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Figure 4 Kaplan Meier crude estimates of time to development of lactic acidosis by initiating regimen.
Figure 5 Kaplan Meier crude estimates of time to development of lipoatrophy by initiating regimen.
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Page 8 of 10comprehensive HIV care and HAART. It allowed for a
relatively long duration of follow up of up to three
years and a fairly high retention rate of 70%, with all
clinicians working on common protocols for defining
the various HAART-associated toxicities. However,
despite this, these findings must be considered in the
light of potential limitations. It is possible that only
severe toxicities that warranted a change in regimen
may have been reported and this may have led to an
u n d e r e s t i m a t i o no ft h er a t e so fs o m eo ft h eH A A R T -
related toxicities, particularly lipoatrophy. Also, plasma
glucose and serum lipid levels were not routinely mea-
sured and thus the true rates for glucose intolerance,
diabetes and dyslipidemia were not attained. Lower
reported rates of the chronic toxicities could also be
related to the rates of death (5%) and loss to follow up
(24%), the majority of which occurred within the first
six months on treatment as described in a previous
report [18].
Conclusion
These results support the move away from stavudine
based regimens towards less toxic combination regimens
as advocated by the World Health Organisation [19,20].
South Africa has implemented these treatment guide-
lines, where tenofovir has now replaced stavudine as
first line therapy. However in resource-limited countries,
where staduvine is still being used because of cost impli-
cations, proper pharmacovigilance systems need to be
established and alternative consensus definitions and
grading protocols are required for identifying various
HAART-related toxicities.
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